News & Events
Showcasing the latest news stories and event headlines from the world of Neurology

‘Big Bang’ of Alzheimer’s points to the origin of the disease

1600 1067 Peter Stevenson, PhD

New research has discovered the precise point at which a healthy protein becomes toxic, offering a window into the very beginnings of Alzheimer’s disease (AD).…

read more

Deep brain stimulation effective in early Parkinson’s tremors

1600 1067 Peter Stevenson, PhD

Deep brain stimulation (DBS) could slow the progression of tremors in Parkinson’s disease (PD), according to new data from a pilot trial.1 Researchers at the…

read more

The EAN President’s take on medical education

1024 625 Mea Holm, PhD

At the recent EAN 2018 congress, we met with Professor Franz Fazekas to discuss important advances and ongoing initiatives in medical education and continuous learning…

read more

Headaches and new ways to crush them

1800 1195 Mea Holm, PhD

At the ‘conference highlights’ session of the 2018 EAN meeting, Professor Isabel Pavão Martins presented a summary of the most groundbreaking research in the field…

read more

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised…

read more

Revolutionary therapies could make spinal muscular atrophy a distant memory

1200 675 Peter Stevenson, PhD

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular…

read more

From prognosis to prevention: Alzheimer’s biomarkers hold significant promise for the future

1200 675 Peter Stevenson, PhD

Biomarkers could change the landscape of Alzheimer’s disease (AD) forever, but we are only just scratching the surface of their potential, the audience heard during…

read more

The many faces of progressive supranuclear palsy

1200 800 Mea Holm, PhD

Progressive supranuclear palsy (PSP)—a neurodegenerative disease characterized by tau pathology—can have a variety of clinical presentations, delegates heard at an EAN 2018 forum talk delivered…

read more

PML risks linked to MS drug duration

1200 797 Peter Stevenson, PhD

Development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is linked to treatment medications, not the MS itself, delegates heard at the recent…

read more

New app aims to facilitate cognitive screening of MS patients

3008 2008 Mea Holm, PhD

Dr. Stephen Rao from the Cleveland Clinic (Ohio, USA) presented a new tablet-based screening method for cognitive dysfunction at the Consortium of Multiple Sclerosis Centers…

read more

Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

1200 829 Peter Stevenson, PhD

New data from a multi-study analysis has unveiled that preclinical Alzheimer’s disease (AD) will not lead to severe dementia in the majority of cases. The…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine…

read more
Brainwork is supported by unrestricted grants from: